Weiss Ratings Reiterates “Sell (D-)” Rating for scPharmaceuticals (NASDAQ:SCPH)

scPharmaceuticals (NASDAQ:SCPH)‘s stock had its “sell (d-)” rating reaffirmed by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other equities research analysts have also commented on the company. Craig Hallum lowered scPharmaceuticals from a “buy” rating to a “hold” rating and set a $6.00 target price on the stock. in a research report on Monday, August 25th. Maxim Group lowered scPharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 25th. Wall Street Zen upgraded scPharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, HC Wainwright lowered scPharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $5.35 target price on the stock. in a research report on Friday, August 29th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, scPharmaceuticals has an average rating of “Reduce” and a consensus price target of $7.78.

scPharmaceuticals Stock Performance

Shares of SCPH stock opened at $5.67 on Wednesday. scPharmaceuticals has a fifty-two week low of $1.94 and a fifty-two week high of $6.28. The firm has a market capitalization of $302.21 million, a price-to-earnings ratio of -3.13 and a beta of 0.31. The stock’s 50-day simple moving average is $5.36 and its 200-day simple moving average is $4.11.

scPharmaceuticals (NASDAQ:SCPH) last issued its earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). The firm had revenue of $16.04 million during the quarter, compared to analysts’ expectations of $15.41 million. scPharmaceuticals had a negative net margin of 183.55% and a negative return on equity of 1,647.86%. As a group, equities analysts forecast that scPharmaceuticals will post -1.53 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. King Luther Capital Management Corp raised its stake in shares of scPharmaceuticals by 13.5% during the 2nd quarter. King Luther Capital Management Corp now owns 3,541,170 shares of the company’s stock worth $13,492,000 after buying an additional 420,000 shares during the period. Rice Hall James & Associates LLC raised its stake in shares of scPharmaceuticals by 41.3% during the 1st quarter. Rice Hall James & Associates LLC now owns 1,398,057 shares of the company’s stock worth $3,677,000 after buying an additional 408,422 shares during the period. Kingdon Capital Management L.L.C. raised its stake in shares of scPharmaceuticals by 25.0% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,000,000 shares of the company’s stock worth $2,630,000 after buying an additional 200,000 shares during the period. Velan Capital Investment Management LP acquired a new position in shares of scPharmaceuticals during the 1st quarter worth approximately $2,413,000. Finally, Tejara Capital Ltd increased its position in shares of scPharmaceuticals by 8.0% during the first quarter. Tejara Capital Ltd now owns 662,052 shares of the company’s stock worth $1,741,000 after purchasing an additional 49,202 shares in the last quarter. 89.52% of the stock is owned by institutional investors and hedge funds.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.